Nature Communications (Nov 2024)

Cancer-associated fibroblast subtypes modulate the tumor-immune microenvironment and are associated with skin cancer malignancy

  • Agnes Forsthuber,
  • Bertram Aschenbrenner,
  • Ana Korosec,
  • Tina Jacob,
  • Karl Annusver,
  • Natalia Krajic,
  • Daria Kholodniuk,
  • Sophie Frech,
  • Shaohua Zhu,
  • Kim Purkhauser,
  • Katharina Lipp,
  • Franziska Werner,
  • Vy Nguyen,
  • Johannes Griss,
  • Wolfgang Bauer,
  • Ana Soler Cardona,
  • Benedikt Weber,
  • Wolfgang Weninger,
  • Bernhard Gesslbauer,
  • Clement Staud,
  • Jakob Nedomansky,
  • Christine Radtke,
  • Stephan N. Wagner,
  • Peter Petzelbauer,
  • Maria Kasper,
  • Beate M. Lichtenberger

DOI
https://doi.org/10.1038/s41467-024-53908-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Cancer-associated fibroblasts (CAFs) play a key role in cancer progression and treatment outcome. This study dissects the intra-tumoral diversity of CAFs in basal cell carcinoma, squamous cell carcinoma, and melanoma using molecular and spatial single-cell analysis. We identify three distinct CAF subtypes: myofibroblast-like RGS5+ CAFs, matrix CAFs (mCAFs), and immunomodulatory CAFs (iCAFs). Large-cohort tissue analysis reveals significant shifts in CAF subtype patterns with increasing malignancy. Two CAF subtypes exhibit immunomodulatory properties via different mechanisms. mCAFs sythesize extracellular matrix and may restrict T cell invasion in low-grade tumors via ensheathing tumor nests, while iCAFs are enriched in late-stage tumors, and express high levels of cytokines and chemokines to aid immune cell recruitment and activation. This is supported by the induction of an iCAF-like phenotype with immunomodulatory functions in primary healthy fibroblasts exposed to skin cancer cell secretomes. Thus, targeting CAF variants holds promise to enhance immunotherapy efficacy in skin cancers.